News

Moderna creator Flagship commits £100M to new London company lab

What's the deal? Flagship Pioneering, the US venture firm that created ModernaDealroom has a profile for this one. Try Dealroom →, has committed an initial £100 million ($132 million) to build Flagship Origination Lab, UK in London — its first company-creation unit outside the US. The lab will "conceive, test, fund and build" AI-native biotech companies in human and planetary health.

What's the endgame? Flagship builds companies from scratch rather than backing existing startups. It plans to recruit and train about 50 scientist-entrepreneurs and operators in the UK, replicating a model that has produced more than 130 companies over 25 years.

Why London? The launch builds on three years in the country, including a London office, a 2023 memorandum of understanding with the UK government, and the transatlantic venture Quotient Therapeutics. Flagship cited the UK's science base, clinical-trial infrastructure, and genomic and health-data assets.

Why now? The move lands during a strong year for UK biotech. The BioIndustry Association puts sector investment at £2.8 billion in the first nine months of 2026, though a £1.6 billion Isomorphic Labs round accounts for much of that.

What could go wrong? The £500 million Flagship hopes to add through partnerships is not yet secured. "We are in discussions with a number of potential partners and have received strong interest," the firm said, but the eventual scale — and startup output — remains unproven.

The signal: Flagship's bet is a notable vote of confidence in UK science at a time when AI-biotech is drawing major capital. Whether its company-building model travels beyond Massachusetts will test both the firm and the market it is entering.

Read more: fiercebiotech.com

Image credit: Generated with Gemini

More top stories